Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-322 versus bevacizumab with carboplatin and paclitaxel for first-line advanced non-squamous non-small cell lung cancer
RBR-48pb9hPhase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Carboplatin + paclitaxel + CT-322 with Carboplatin + paclitaxel + bevacizumab + placebo (2 arms). Started Jul 2010; status: recruiting.
02
Drugs
pegdinetanibbevacizumabcarboplatinpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on RBR-48pb9h.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-48pb9h.